Novelion Therapeutics’ Request to Voluntarily Delist from the Toronto Stock Exchange Granted
April 19 2017 - 4:15PM
Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), a
biopharmaceutical company dedicated to developing new standards of
care for individuals living with rare diseases, today announced
that, as part of its cost rationalization process, the Company’s
request to voluntarily delist its common shares on the Toronto
Stock Exchange ("TSX") at the close of markets on May 3, 2017 has
been granted. The Company’s shares will continue to trade on the
NASDAQ Global Select Market under the symbol “NVLN”.
The Company believes that the low trading volume of its shares
on the TSX over a sustained period no longer justifies the
financial and administrative costs associated with maintaining a
dual listing. Canadian shareholders will be able to continue to
trade the Company’s shares on the NASDAQ exchange through their
brokers who have U.S. registered broker-dealer affiliates.
About Novelion Therapeutics Novelion
Therapeutics is a biopharmaceutical company dedicated to developing
new standards of care for individuals living with rare diseases.
Novelion has a diversified commercial portfolio through its
indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes
MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate
for the treatment of inherited retinal disease caused by underlying
mutations in RPE65 or LRAT genes. The company seeks to advance its
portfolio of rare disease therapies by investing in science and
clinical development.
CONTACT:
Amanda Murphy, Director, Investor Relations & Corporate Communications
Novelion Therapeutics
857-242-5024
Amanda.murphy@novelion.com
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Apr 2023 to Apr 2024